Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022

New treatment possibilities and modalities are now available globally for patients with haemophilia requiring surgery or invasive procedures.

[1]  L. Frenzel,et al.  Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B) , 2021, Blood.

[2]  B. Nolan,et al.  Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  G. Benson,et al.  Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials , 2021, Blood.

[4]  S. Robson,et al.  Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis , 2021, Blood.

[5]  A. Dougall,et al.  Single centre, real‐world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  C. Hermans,et al.  Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report , 2021, Therapeutic advances in hematology.

[7]  J. Motwani,et al.  Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  V. Jiménez‐Yuste,et al.  Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  C. Berger,et al.  Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors , 2021, Pediatric blood & cancer.

[10]  B. Guillet,et al.  Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor , 2021, TH open : companion journal to thrombosis and haemostasis.

[11]  K. Nogami,et al.  Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis , 2021, International Journal of Hematology.

[12]  J. Mahlangu,et al.  The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing , 2021, The Lancet.

[13]  L. Alberio,et al.  Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. , 2020, Swiss medical weekly.

[14]  J. Oldenburg,et al.  Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. , 2020, Blood.

[15]  M. Lewandowska,et al.  Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  M. Franchini,et al.  Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  I. Welsby,et al.  Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab. , 2020, Journal of cardiothoracic and vascular anesthesia.

[18]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  G. Kenet,et al.  Emicizumab treatment and monitoring in a paediatric cohort: real‐world data , 2020, British journal of haematology.

[20]  C. Königs,et al.  Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A , 2020, Hämostaseologie.

[21]  Jeffrey S. Stonebraker,et al.  The World Federation of Hemophilia Annual Global Survey 1999‐2018 , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  R. Butler,et al.  Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  M. Eyster,et al.  Total knee replacement with and without emicizumab: a unique comparison of perioperative management. , 2020, Blood advances.

[24]  E. Santagostino,et al.  Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring , 2020, British journal of haematology.

[25]  E. Santagostino,et al.  Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. , 2020, Blood transfusion = Trasfusione del sangue.

[26]  C. Hermans,et al.  EHL‐FIX in haemophilia B carriers with FIX deficiency , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  J. Astermark,et al.  Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. , 2019, Blood.

[28]  M. Ragni,et al.  Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  R. Herzog,et al.  A Molecular Revolution in the Treatment of Hemophilia. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  E. Santagostino,et al.  Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. , 2019, Thrombosis research.

[31]  J. Oldenburg,et al.  A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. , 2019, Blood.

[32]  H. Kiyoi,et al.  Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors , 2019, TH Open.

[33]  E. Santagostino,et al.  Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement , 2019, Haematologica.

[34]  R. Gruppo,et al.  Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  J. Oldenburg,et al.  Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A , 2019, Thrombosis and Haemostasis.

[36]  M. Ragni,et al.  Emicizumab use in major orthopedic surgery. , 2019, Blood advances.

[37]  C. Hermans,et al.  Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. , 2019, The Lancet. Haematology.

[38]  Hande Kızılocak,et al.  Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays , 2019, Therapeutic advances in hematology.

[39]  S. Meeks,et al.  Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis , 2018, Blood.

[40]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.

[41]  L. V. van Vulpen,et al.  Continuous infusion of extended half‐life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[42]  M. Makris,et al.  Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  J. Oldenburg,et al.  Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2) , 2017 .

[44]  O. Christophe,et al.  Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? , 2017, Blood.

[45]  A. Akinc,et al.  Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy , 2017, The New England journal of medicine.

[46]  E. Santagostino,et al.  First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[47]  S. Diop,et al.  Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal , 2017, BMC Hematology.

[48]  P. Giangrande,et al.  Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[49]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors. , 2017, The New England journal of medicine.

[50]  J. Oldenburg,et al.  Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[51]  E. Santagostino,et al.  Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[52]  Tetsuji Sato,et al.  Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.

[53]  C. Hermans,et al.  Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study , 2015, British journal of haematology.

[54]  C. Hermans,et al.  Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[55]  C. Hermans,et al.  Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[56]  B. George,et al.  Fracture neck of femur in haemophilia A – experience from a cohort of 11 patients from a tertiary centre in India , 2007, Haemophilia.

[57]  B. George,et al.  Surgery for hemophilia in developing countries. , 2005, Seminars in thrombosis and hemostasis.

[58]  M. Chandy,et al.  External fixators in haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[59]  A. Srivastava.  Factor replacement therapy in haemophilia – are there models for developing countries? , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[60]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[61]  Srivastava,et al.  Low‐dose intermittent factor replacement for post‐operative haemostasis in haemophilia , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[62]  Pathare,et al.  Surgery in Haemophilia: experience from a centre in India , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[63]  A. Srivastava,et al.  Low‐dose activated factor IX complex concentrates (FEIBAR) for post‐operative haemostasis in a patient with high responding factor VIII inhibitors , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[64]  M. Chandy,et al.  Surgery in patients with congenital coagulation disorders. , 1994, The National medical journal of India.

[65]  S. Schulman,et al.  Adjusted dose continuous infusion of factor VIII in patients with haemophilia A , 1992, British journal of haematology.